Spyre Therapeutics Stock Forecast

Stock Price Forecast

According to 17 analysts polled by S&P Global, Spyre Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $100.47. The average 1-year stock price forecast is 14.31% higher than the current stock price, while the lowest is $78 (-11.25%) and the highest is $135 (+53.60%).

Price Target: $100.47 (+14.31%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$78	$100.47	$100	$135
Change	-11.25%	+14.31%	+13.78%	+53.60%

Analyst Ratings

The average analyst rating for Spyre Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	16	16	16	17	17	17
Buy	0	0	0	0	0	0
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	16	16	16	17	17	17

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
David Hoang Deutsche Bank	Deutsche Bank	Buy Reiterates $115 → $135	Buy	Reiterates	$115 → $135	+53.60%	Jun 23, 2026
Tyler Van Buren TD Cowen	TD Cowen	Buy Maintains n/a	Buy	Maintains	n/a	n/a	Jun 23, 2026
Alex Thompson CFA Stifel Nicolaus	Stifel Nicolaus	Buy Reiterates $107	Buy	Reiterates	$107	+21.74%	Jun 22, 2026
David Nierengarten Wedbush	Wedbush	Buy Maintains $80 → $100	Buy	Maintains	$80 → $100	+13.78%	Jun 16, 2026
Akash Tewari Jefferies	Jefferies	Buy Maintains $95 → $98	Buy	Maintains	$95 → $98	+11.50%	Jun 16, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-2.95

from -1.98

EPS Next Year

-3.13

from -2.95

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	18.74M	2.33M	886.00K	-	-	-
Operating Income	-65.65M	-84.78M	-117.61M	-208.57M	-219.56M	-282.02M
Net Income	-65.80M	-83.82M	-338.79M	-208.02M	-155.20M	-272.57M
EPS	-	-	-	-	-1.98	-2.95
Free Cash Flow	-30.62M	-50.01M	-9.61M	-66.57M	-103.85M	-185.33M
No. Analysts	-	-	-	-	-	12

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Revenue Growth	2027	2028
High	-
Avg	-
Low	-

EPS Forecast

EPS	2026	2027	2028
High	-2.29
Avg	-2.95
Low	-3.82

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-